A cheap gout medication, colchicine, shows significant promise in preventing heart attacks and strokes for individuals with ...

WASHINGTON, DC — Use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduced the need for urate-lowering therapy (ULT) and gout flare therapies in people who had both type 2 diabetes (T2D) and ...

A low dose of colchicine — a commonly used gout drug — helped reduce the risk of heart attack and stroke in people with ...

October 2, 2012 — New gout guidelines from the American College of Rheumatology are meant to improve gout management by providing clinicians with clear, readily implemented guidance on urate-lowering ...

Researchers Found a Drug That Reduces Heart Attack Risk. It's as Low as $5. HAVING A HEART attack can be a scary and ...

A widely available drug used for gout may help prevent heart attacks and stroke in people with cardiovascular disease. | Drug ...

LONDON, June 8 (Reuters) - A drug used for more than 40 years to treat gout could also offer a cheap alternative to more modern heart drugs from Roche and Servier for patients with chronic chest pain, ...

For gout pain that does not respond to conventional therapies, patients’ only remaining option is a drug from Amgen. But this biologic medicine introduces the same problem facing every therapeutic ...

A widely-used, inexpensive gout drug could reduce heart attacks and strokes in people with cardiovascular disease, according to a new Cochrane review. The review examined the effects of low doses of ...

The MarketWatch News Department was not involved in the creation of this content. -- Results of a Phase 2a dose escalating study of lingdolinurad (ABP-671) for chronic gout, which enrolled patients ...

East Brunswick’s Savient Pharmaceuticals Inc. is starting the new year with a major boost. Savient’s chronic gout drug, Krystexxa, now has its own permanent billing code from the Centers for Medicare ...

* FDA "can not at this time" approve drug application * Seeks meeting with FDA * Seeks to resubmit application by early 2010 (Adds wording from letter in second paragraph) NEW YORK, Aug 2 (Reuters) - ...